Publication

Article

CURE

Summer 2007
Volume6
Issue 4

www.re-mission.net

Author(s):

Elizabeth Whittington

Gamers take virtual shot at cancer.

Teens and young adults fighting cancer can now really battle the disease with Re-Mission, a video game that pits a robot called Roxxi against cancer cells and bacterial infections, while dealing with side effects at a microscopic level within the bodies of fictional patients. HopeLab, a nonprofit focused on children with chronic illnesses, developed the video game with game developers, animators, psychologists, and scientists. Re-Mission is available free at www.re-mission.net. The website also offers an online community for teens and young adults with cancer.

Articles in this issue
How to Find Help
Job Transitions, Insurance Change
Medicare Coverage for Colon Cancer Screenings
Noting Group Differences
The Journey of Cancer Survivorship
Beauty Shopping
Pregnancy After Cancer
Fast Facts: Richard Roundtree
Portal Authority
Precious Tumor
Surviving "Survivor" Stereotypes
The Secret of Caregivers
Surgeons and Robots
A Hole In The World
Making the Most of a Portal

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with black hair.
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Related Content
Illustration of blood.
April 24th 2025

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

Ryan Scott
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting: © stock.adobe.com.
April 18th 2025

Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma

Alex Biese
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of lymphoma survivor Linda Cohen
April 9th 2025

Going Off Medication for Lymphoma: Could It Be True?

Linda Cohen
After living with lymphoma for 15 and a half years, my doctor has suggested reducing the dose of my medication and possibly taking me off of it.
Image of FDA sign.
April 8th 2025

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

Spencer Feldman
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.